Journal
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY
Volume 22, Issue 12, Pages 1067-1076Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0192-0561(00)00075-8
Keywords
cancer; immunotherapy; thymosin alpha 1
Categories
Ask authors/readers for more resources
Many studies have explored the effects of immunotherapy, alone or in combination with conventional therapies, on both experimental and human cancers. Evidence has been provided that combined treatments with thymosin alpha 1 (T alpha 1) and low doses of interferon (IFN) or interleukin (IL)-2 are highly effective in restoring several immune responses depressed by tumor growth and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to increase the anti-tumor effect of chemotherapy while markedly reducing the general toxicity of the treatment. The advantages of using this combined chemo-immunotherapeutic approach in experimental and human cancers are reviewed in this issue. (C) 2000 International Society for Immunopharmacology. Published by Elsevier Science Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available